What Lies Beyond Health Reform: Pfizer's Kindler Talks Innovation, Jobs
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA's incoming chairman, Pfizer CEO Jeff Kindler, is pushing redoubled efforts toward a public/private solution on advancing innovation within the U.S. biopharmaceutical industry. As the fate of health reform remains uncertain, he discusses over-arching goals and challenges for the industry in the year ahead.
You may also be interested in...
Enrolling 31 Mil.: Families USA Pushing Cooperative Plan To Pharma, Others
Consumer health care advocacy group Families USA is working to catalyze formation of a health care stakeholder cooperative, including pharmaceutical firms, insurers and hospitals, to help 31 million uninsured individuals obtain the coverage that would be provided under health reform legislation pending in Congress - assuming the legislation passes
PhRMA Chief Billy Tauzin Stepping Down
Billy Tauzin is stepping down as president and CEO of the Pharmaceutical Research and Manufacturers of America
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.